CEL-SCI Initiates Development of Immunotherapy to Treat COVID-19 Coronavirus Infection.

CEL-SCI reports recent data review by the Independent Data Monitoring Committee for its pivotal Phase 3 head and neck cancer study.

NEW YORK, NY / ACCESSWIRE / March 10, 2020 / Levi & Korsinsky announces it has commenced an investigation of CEL-SCI Corporation (NYSE:CVM) concerning possible breaches of fiduciary duty. To obtain additional ...

CEL-SCI to Develop LEAPS COVID-19 Immunotherapy in Collaboration with University of Georgia Center for Vaccines and Immunology

By John Vandermosten, CFA NYSE:CVM READ THE FULL CVM RESEARCH REPORT The Last Review? CEL-SCI Corporation (NYSE:CVM) today announced its second Independent Data Monitoring Committee (IDMC) review this year for the IT MATTERS Phase III Multikine study for head and neck cancer. We believe that the longer than expected duration of the trial combined with the IDMC recommendation to continue its

Important update for CEL-SCI Corporation Annual Meeting of Shareholders.

Oil stocks are extend their losing streak into day five as fears of the coronavirus continue. Blue Line Futures President Bill Baruch joins Yahoo Finance’s On the Move to discuss.

Hedge funds are known to underperform the bull markets but that's not because they are terrible at stock picking. Hedge funds underperform because their net exposure in only 40-70% and they charge exorbitant fees. No one knows what the future holds and how market participants will react to the bountiful news that floods in each […]

VIENNA, VA / ACCESSWIRE / December 6, 2019 / CEL-SCI Corporation (NYSE American:CVM), a Phase 3 cancer immunotherapy company, today announced that it will be presenting at the 12th annual LD Micro Main Event on Tuesday, December 10, 2019 at 2:00 PM PST or 5:00 PM EST. The Chief Executive Officer, Geert Kersten, will be presenting and meeting with investors. To access the live webcast and subsequent archived recordings for the presentation, please visit the Investor Relations section of the Company's website at https://cel-sci.com/new-investor-information/.

Companies In The News Are: SSNT, NLNK, CVM, AXE

CEL-SCI announces the closing of its $7.7 million bought deal.

CEL-SCI Corporation reports second quarter fiscal 2020 financial results.

CEL-SCI’s Pivotal Phase 3 Study has reached the required number of events to evaluate data for Multikine in treatment of Head and Neck Cancer.

By John Vandermosten, CFA NYSE:CVM CEL-SCI Corporation (NYSE:CVM) announced on May 4, 2020 that it had achieved the targeted number of events for its IT MATTERS trial for head and neck cancer. The trial enrolled its first patients in 2011 in the US, Canada, UK, France and 20 other countries. The primary endpoint for the study is an overall survival benefit of 10% over standard of care alone in

CEL-SCI announces change of location to 2020 Annual Meeting of Shareholders.

By John Vandermosten, CFA NYSE:CVM We joined CEL-SCI Corporation (NYSE:CVM) on a visit with Texas investors yesterday which coincided with a roller coaster ride in the stock. Company CEO Geert Kersten updated current investors, introduced the stock to new investors and provided a status report for the IT-MATTERS Phase III clinical trial for Multikine. Mr. Kersten highlighted the company’s

CEL-SCI announces bought deal offering.

CEL-SCI increases previously announced bought deal to $7.7 million